Rigosertib Sodium

N/A

Report date: 2026/04/28 20:00:22
NME

Base Information

Drug NameRigosertib Sodium
Drug Alias NameNovonex利戈色替利戈舍替Estybon瑞格色替 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitorsPolo like kinase 1 inhibitorsCyclin-dependent kinase 1 inhibitors
TargetsCyclin-dependent kinase 1PI3-kinase class IPolo like kinase 1
Therapy Area/IndicationsSkin MelanomaPenile Squamous Cell CarcinomaSolid tumours +[34] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaIND
Originator CompaniesTraws Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesSpecialised Therapeutics AustraliaKnight TherapeuticsAlidac Pharmaceuticals Ltd +[9] 
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterNational Heart, Lung, And Blood Institute (Nhlbi)SymBio Pharmaceuticals Ltd
Active IndicationsSkin MelanomaEpidermolysis Bullosa DystrophicaMyelodysplastic Syndromes +[8] 
Inactive IndicationsPenile Squamous Cell CarcinomaSolid tumoursCytopenia +[26] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG